This general trend of a reduction in median CA-125 concentrations during combination therapy was also observed in subgroup analyses of patients with Pt-S disease and Pt-R disease, but not in patients with Pt-Rf disease. This evidence concerns the gene MUC16 and glycogen storage disease VI.